Selander KS - Search Results

1

Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells.

Suarez-Cuervo C, Harris KW, Kallman L, Väänänen HK, Selander KS. Suarez-Cuervo C, et al. Among authors: selander ks. Breast Cancer Res Treat. 2003 Jul;80(1):71-8. doi: 10.1023/a:1024443303436. Breast Cancer Res Treat. 2003. PMID: 12889600

2

Liposome-encapsulated zoledronate increases inflammatory macrophage population in TNBC tumours.

Petruk N, Sousa S, Croset M, Polari L, Zlatev H, Selander K, Mönkkönen J, Clézardin P, Määttä J. Petruk N, et al. Eur J Pharm Sci. 2023 Nov 1;190:106571. doi: 10.1016/j.ejps.2023.106571. Epub 2023 Aug 29. Eur J Pharm Sci. 2023. PMID: 37652236 Free article.

3

The effects of bisphosphonates on the resorption cycle of isolated osteoclasts.

Selander K, Lehenkari P, Väänänen HK. Selander K, et al. Calcif Tissue Int. 1994 Nov;55(5):368-75. doi: 10.1007/BF00299317. Calcif Tissue Int. 1994. PMID: 7532540

4

Calcitonin promotes osteoclast survival in vitro.

Selander KS, Härkönen PL, Valve E, Mönkkönen J, Hannuniemi R, Väänänen HK. Selander KS, et al. Mol Cell Endocrinol. 1996 Sep 18;122(2):119-29. doi: 10.1016/0303-7207(96)03870-1. Mol Cell Endocrinol. 1996. PMID: 8902842

5

Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.

Selander KS, Mönkkönen J, Karhukorpi EK, Härkönen P, Hannuniemi R, Väänänen HK. Selander KS, et al. Mol Pharmacol. 1996 Nov;50(5):1127-38. Mol Pharmacol. 1996. PMID: 8913344

6

Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.

Heikkinen JE, Selander KS, Laitinen K, Arnala I, Väänänen HK. Heikkinen JE, et al. Among authors: selander ks. J Bone Miner Res. 1997 Jan;12(1):103-10. doi: 10.1359/jbmr.1997.12.1.103. J Bone Miner Res. 1997. PMID: 9240732 Free article. Clinical Trial.

7

Purification and characterization of the yeast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis.

Burns S, Arcasoy MO, Li L, Kurian E, Selander K, Emanuel PD, Harris KW. Burns S, et al. Blood. 2002 Jun 15;99(12):4400-5. doi: 10.1182/blood.v99.12.4400. Blood. 2002. PMID: 12036868 Free article.

8

Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition.

Merrell M, Suarez-Cuervo C, Harris KW, Väänänen HK, Selander KS. Merrell M, et al. Among authors: selander ks. Breast Cancer Res Treat. 2003 Oct;81(3):231-41. doi: 10.1023/a:1026126430905. Breast Cancer Res Treat. 2003. PMID: 14620918

9

Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy.

Selander KS, Li L, Watson L, Merrell M, Dahmen H, Heinrich PC, Müller-Newen G, Harris KW. Selander KS, et al. Cancer Res. 2004 Oct 1;64(19):6924-33. doi: 10.1158/0008-5472.CAN-03-2516. Cancer Res. 2004. PMID: 15466183

10

Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice.

Suarez-Cuervo C, Merrell MA, Watson L, Harris KW, Rosenthal EL, Väänänen HK, Selander KS. Suarez-Cuervo C, et al. Among authors: selander ks. Clin Exp Metastasis. 2004;21(6):525-33. doi: 10.1007/s10585-004-3503-x. Clin Exp Metastasis. 2004. PMID: 15679050

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters